Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.
Melinda L TelliHiroshi NagataIrene WapnirChaitanya R AcharyaKaitlin ZablotskyBernard A FoxCarlo B BifulcoShawn M JensenCarmen Ballesteros-MerinoMai Hope LeRobert H PierceErica BrowningReneta HermizLauren SvensonDonna BannavongKim JaffeJendy SellKellie Malloy FoerterDavid A CantonChristopher G TwittyTakuya OsadaHerbert Kim LyerlyErika J CrosbyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
These data show a safe, effective intratumoral therapy that can enhance antigen presentation and recruit CD8 T cells, which are required for the antitumor efficacy. We identify a Tavo treatment-related gene signature associated with improved outcomes and conversion of nonresponsive tumors, potentially even beyond TNBC.
Keyphrases
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- copy number
- genome wide
- ejection fraction
- escherichia coli
- genome wide identification
- type diabetes
- dna methylation
- mesenchymal stem cells
- skeletal muscle
- metabolic syndrome
- case report
- signaling pathway
- insulin resistance
- induced apoptosis
- transcription factor
- artificial intelligence
- genome wide analysis
- smoking cessation
- endoplasmic reticulum stress